Biomarin Pharmaceutical (BMRN) Return on Equity (2010 - 2026)

Biomarin Pharmaceutical has disclosed Return on Equity across 17 years of filings, most recently posting 0.0% for Q1 2026.

• Quarterly Return on Equity changed 0.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
• Return on Equity declined to 0.0% in Q1 2026, from 0.0% in the prior quarter.
• Over five years, Return on Equity peaked at 0.0% in Q2 2025 and troughed at 0.0% in Q1 2022.
• A 5-year average of 0.0% and a median of 0.0% in 2024 frame the typical range for Return on Equity.
• Biggest YoY gain for Return on Equity was 0 bps in 2022; the steepest drop was 0 bps in 2022.
• Tracing BMRN's Return on Equity over 5 years: stood at 0.0% in 2022, then rose by 10 bps to 0.0% in 2023, then soared by 126 bps to 0.0% in 2024, then dropped by 25 bps to 0.0% in 2025, then retreated by 24 bps to 0.0% in 2026.
• Business Quant data shows BMRN's Return on Equity at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.